TCL Archive Avastin Vote Puts Focus On FDA Criteria In First-Line Metastatic Breast Cancer: Is PFS Good Enough? December 14, 2007
TCL Archive Extent Of Risk Reduction From Ovary Removal Varies According To BRCA Mutation February 29, 2008
TCL Archive FDA, NCI united in pursuit of 2015 goal, Andrew von Eschenbach tells cancer center directors; says his appointment was necessary to “maintain the momentum of the FDA.” October 21, 2005
